Bayer presented six studies and Bayer stock trades above EUR 43.77

Published on 10/12/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer's first-half sales rose 3.00 percent to EUR 24.30 billion. Bayer stock costs EUR 43.87 on October 12, 2026 versus EUR 43.77.

Key points in brief

Bayer presented one late-breaking presentation and five posters at the HFSA meeting from October 9 to October 12, 2026.
First-half 2026 sales rose 3.00 percent to EUR 24.30 billion, while core earnings per share reached EUR 3.66.
Bayer announced a USD 2.20 billion pharmaceutical manufacturing site in Ohio on October 2, 2026.
Bayer stock was at EUR 43.87 at Lang & Schwarz on October 12, 2026, 0.23 percent above the Xetra close of October 9, 2026.

Pop-Art-Comicpanel: begeisterter Forscher im weißen Kittel hält Reagenzglas triumphierend hoch, große Sprechblase mit DISCOVERY!, gelber Hintergrund mit roten Rasterpunkten, blauer Explosionsstern — Pop-Art-Comic im Lichtenstein-Stil: Forscher im Kittel hält jubilierend Reagenzglas hoch, Sprechblase DISCOVERY!, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 43.87 at Lang & Schwarz on October 12, 2026, at 10:38 a.m. CEST, up EUR 0.10 or 0.23 percent versus the Xetra close of October 9, 2026, at EUR 43.77. On October 8, Bayer announced one late-breaking presentation and five posters for the Heart Failure Society of America meeting, which ran from October 9 to October 12, 2026, according to Business Wire. The event adds a clinical update to a stock picture shaped by pharmaceuticals, Crop Science and litigation exposure.

Cardiovascular pipeline gains attention

Bayer's HFSA program included late-breaking Phase III data on iodine 124 evuzamitide in suspected cardiac amyloidosis and study designs for three ongoing Kerendia heart-failure trials. The company also presented two retrospective studies on steroidal mineralocorticoid receptor antagonist use, giving the meeting a total of six listed presentations.

The clinical portfolio matters because Bayer is trying to offset pressure in mature medicines with new growth drivers. In the second quarter of 2026, Kerendia sales increased 83.00 percent year over year, while Nubeqa sales rose 64.00 percent, according to the Q2 earnings-call transcript published by Yahoo Finance. Those figures contrast with second-quarter Eylea sales down 33.00 percent and Xarelto sales down 42.00 percent.

Three dated signals shape the stock

On October 1, JPMorgan analyst Richard Vosser rated Bayer Overweight and set a EUR 61.00 price target, while warning that third-quarter expectations could be high, as reported by Borse Express. On October 2, Bayer announced a USD 2.20 billion pharmaceutical manufacturing site in New Albany, Ohio, with the first module planned for 2031, according to Bayer. The October 8 HFSA announcement was the third dated signal, linking the current stock story to pipeline development rather than to a single earnings surprise.

What does the Ohio site add?

The Ohio project broadens Bayer's U.S. production footprint for oncology, cardiovascular and renal medicines. Bayer plans a second manufacturing module for 2034, so the investment is a long-duration capacity decision rather than an immediate earnings driver. Its strategic value therefore depends on demand for the pipeline and on execution across the two planned modules.

Results date sets the next test

Bayer's first-half 2026 sales increased 3.00 percent to EUR 24.30 billion, while EBITDA before special items rose 7.00 percent to EUR 6.60 billion and core earnings per share reached EUR 3.66, according to Yahoo Finance. Free cash flow was negative EUR 2.70 billion in the first half, compared with negative EUR 1.40 billion a year earlier, with litigation-related payments cited in the call.

Bayer's next reporting date is November 3, 2026, when it is scheduled to publish its third-quarter statement, investor video call and media update, according to the company's Bayer financial calendar.

Stock stays above the Xetra close

Bayer stock was trading at EUR 43.87 at Lang & Schwarz on October 12, 2026, at 10:38 a.m. CEST, 0.23 percent above the Xetra close of October 9, 2026, at EUR 43.77. The price was also above the EUR 43.17 200-day average cited by Borse Express, leaving the upcoming third-quarter report as the next scheduled test for operating momentum. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.